Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Total Liabilities: 2017-2024

Historic Total Liabilities for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Dec 2024 value amounting to $109.8 million.

  • Crinetics Pharmaceuticals' Total Liabilities rose 18.65% to $123.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $123.9 million, marking a year-over-year increase of 18.65%. This contributed to the annual value of $109.8 million for FY2024, which is 14.07% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Total Liabilities of $109.8 million as of FY2024, which was up 14.07% from $96.2 million recorded in FY2023.
  • In the past 5 years, Crinetics Pharmaceuticals' Total Liabilities ranged from a high of $109.8 million in FY2024 and a low of $14.5 million during FY2020.
  • In the last 3 years, Crinetics Pharmaceuticals' Total Liabilities had a median value of $96.2 million in 2023 and averaged $80.6 million.
  • Data for Crinetics Pharmaceuticals' Total Liabilities shows a peak YoY surged of 168.49% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Crinetics Pharmaceuticals' Total Liabilities stood at $14.5 million in 2020, then soared by 31.29% to $19.1 million in 2021, then surged by 87.97% to $35.8 million in 2022, then surged by 168.49% to $96.2 million in 2023, then climbed by 14.07% to $109.8 million in 2024.